Full Text Journal Articles by
Author Robert L Vessella

Advertisement

Find full text journal articles






A positive role of c-Myc in regulating androgen receptor and its splice variants in prostate cancer.

Shanshan Bai, Subing Cao, Lianjin Jin, Margaret Kobelski, Blake Schouest, Xiaojie Wang, Nathan Ungerleider, Melody Baddoo, Wensheng Zhang, Eva Corey, Robert L Vessella, Xuesen Dong, Kun Zhang, Xianghui Yu, Erik K Flemington, Yan Dong,

Increased expression of the full-length androgen receptor (AR-FL) and AR splice variants (AR-Vs) drives the progression of castration-resistant prostate cancer (CRPC). The levels of AR-FL and AR-V transcripts are often tightly correlated in individual CRPC samples, yet our understanding of how their expression is co-regulated is limited. Here, we report ... Read more >>

Oncogene (Oncogene)
[2019, 38(25):4977-4989]

Cited: 5 times

View full text PDF listing >>



Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models.

Nora M Navone, Wytske M van Weerden, Robert L Vessella, Elizabeth D Williams, Yuzhuo Wang, John T Isaacs, Holly M Nguyen, Zoran Culig, Gabri van der Pluijm, Cyril A Rentsch, Rute B Marques, Corrina M A de Ridder, Lukas Bubendorf, George N Thalmann, William Nathaniel Brennen, Frédéric R Santer, Patrizia L Moser, Peter Shepherd, Eleni Efstathiou, Hui Xue, Dong Lin, Jeroen Buijs, Tjalling Bosse, Anne Collins, Norman Maitland, Mark Buzza, Michelle Kouspou, Ariel Achtman, Renea A Taylor, Gail Risbridger, Eva Corey,

BACKGROUND:While it has been challenging to establish prostate cancer patient-derived xenografts (PDXs), with a take rate of 10-40% and long latency time, multiple groups throughout the world have developed methods for the successful establishment of serially transplantable human prostate cancer PDXs using a variety of immune deficient mice. In 2014, ... Read more >>

Prostate (The Prostate)
[2018, 78(16):1262-1282]

Cited: 9 times

View full text PDF listing >>



Advertisement

Plasma Fatty Acids as Surrogate for Prostate Levels.

Jeannette M Schenk, Xiaoling Song, Colm Morrissey, Robert L Vessella, Daniel W Lin, Marian L Neuhouser,

Inconsistent results from epidemiologic studies of circulating fatty acids and prostate cancer risk may be partly due to use of blood concentrations as surrogate biomarkers of prostate tissue concentrations. To determine whether blood concentrations reflect prostate tissue fatty acid profiles, we evaluated associations between phospholipid fatty acid (PLFA) profiles measured ... Read more >>

Nutr Cancer (Nutrition and cancer)
[2018, 70(1):45-50]

Cited: 0 times

View full text PDF listing >>



Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling.

Eric G Bluemn, Ilsa M Coleman, Jared M Lucas, Roger T Coleman, Susana Hernandez-Lopez, Robin Tharakan, Daniella Bianchi-Frias, Ruth F Dumpit, Arja Kaipainen, Alexandra N Corella, Yu Chi Yang, Michael D Nyquist, Elahe Mostaghel, Andrew C Hsieh, Xiaotun Zhang, Eva Corey, Lisha G Brown, Holly M Nguyen, Kenneth Pienta, Michael Ittmann, Michael Schweizer, Lawrence D True, David Wise, Paul S Rennie, Robert L Vessella, Colm Morrissey, Peter S Nelson,

Androgen receptor (AR) signaling is a distinctive feature of prostate carcinoma (PC) and represents the major therapeutic target for treating metastatic prostate cancer (mPC). Though highly effective, AR antagonism can produce tumors that bypass a functional requirement for AR, often through neuroendocrine (NE) transdifferentiation. Through the molecular assessment of mPCs ... Read more >>

Cancer Cell (Cancer cell)
[2017, 32(4):474-489.e6]

Cited: 108 times

View full text PDF listing >>



LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics.

Holly M Nguyen, Robert L Vessella, Colm Morrissey, Lisha G Brown, Ilsa M Coleman, Celestia S Higano, Elahe A Mostaghel, Xiaotun Zhang, Lawrence D True, Hung-Ming Lam, Martine Roudier, Paul H Lange, Peter S Nelson, Eva Corey,

BACKGROUND:Metastatic prostate cancer is a common and lethal disease for which there are no therapies that produce cures or long-term durable remissions. Clinically relevant preclinical models are needed to increase our understanding of biology of this malignancy and to evaluate new agents that might provide effective treatment. Our objective was ... Read more >>

Prostate (The Prostate)
[2017, 77(6):654-671]

Cited: 42 times

View full text PDF listing >>



Src promotes castration-recurrent prostate cancer through androgen receptor-dependent canonical and non-canonical transcriptional signatures.

Indranil Chattopadhyay, Jianmin Wang, Maochun Qin, Lingqiu Gao, Renae Holtz, Robert L Vessella, Robert W Leach, Irwin H Gelman,

Progression of prostate cancer (PC) to castration-recurrent growth (CRPC) remains dependent on sustained expression and transcriptional activity of the androgen receptor (AR). A major mechanism contributing to CRPC progression is through the direct phosphorylation and activation of AR by Src-family (SFK) and ACK1 tyrosine kinases. However, the AR-dependent transcriptional networks ... Read more >>

Oncotarget (Oncotarget)
[2017, 8(6):10324-10347]

Cited: 5 times

View full text PDF listing >>



Characterization of an Abiraterone Ultraresponsive Phenotype in Castration-Resistant Prostate Cancer Patient-Derived Xenografts.

Hung-Ming Lam, Ryan McMullin, Holly M Nguyen, Ilsa Coleman, Michael Gormley, Roman Gulati, Lisha G Brown, Sarah K Holt, Weimin Li, Deborah S Ricci, Karin Verstraeten, Shibu Thomas, Elahe A Mostaghel, Peter S Nelson, Robert L Vessella, Eva Corey,

Purpose: To identify the molecular signature associated with abiraterone acetate (AA) response and mechanisms underlying AA resistance in castration-resistant prostate cancer patient-derived xenografts (PDXs).Experimental Design: SCID mice bearing LuCaP 136CR, 77CR, 96CR, and 35CR PDXs were treated with AA. Tumor volume and prostate-specific antigen were monitored, and tumors were harvested ... Read more >>

Clin. Cancer Res. (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2017, 23(9):2301-2312]

Cited: 6 times

View full text PDF listing >>



GRM1 is An Androgen-Regulated Gene and its Expression Correlates with Prostate Cancer Progression in Pre-Clinical Models.

Mojgan Shourideh, Gissou Azabdaftari, Kristopher Attwood, Adam DePriest, Kristine M Wadosky, Bryan M Gillard, Ellen Karasik, Hannelore Heemers, Natasha Kyprianou, Irwin H Gelman, Eva Corey, Robert L Vessella, James L Mohler, Shahriar Koochekpour,

PURPOSE:We recently demonstrated that glutamate receptor GRM1 was expressed at high levels in castration-resistant prostate cancer (CR-PCa) tissues and cells. Herein, we determined the relationship between GRM1 and AR, PSA, and tumor growth, remission, and recurrence in preclinical PCa models. The effect of alterations in GRM1 expression was also investigated ... Read more >>

Clin. Cancer Res. (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2016, :]

Cited: 1 time

View full text PDF listing >>



Amplification of the 9p13.3 chromosomal region in prostate cancer.

Leena Latonen, Katri A Leinonen, Teemu Grönlund, Robert L Vessella, Teuvo L J Tammela, Outi R Saramäki, Tapio Visakorpi,

Amplification of the 9p13.3 chromosomal region occurs in a subset of prostate cancers (PCs); however, the target gene or genes of this amplification have remained unidentified. The aim of this study was to investigate the 9p13.3 amplification in more detail to identify genes that are potentially advantageous for cancer cells. ... Read more >>

Genes Chromosomes Cancer (Genes, chromosomes & cancer)
[2016, 55(8):617-625]

Cited: 3 times

View full text PDF listing >>



s-SHIP expression identifies a subset of murine basal prostate cells as neonatal stem cells.

Guillaume Brocqueville, Renee S Chmelar, Hélène Bauderlique-Le Roy, Emeric Deruy, Lu Tian, Robert L Vessella, Norman M Greenberg, Larry R Rohrschneider, Roland P Bourette,

Isolation of prostate stem cells (PSCs) is crucial for understanding their biology during normal development and tumorigenesis. In this aim, we used a transgenic mouse model expressing GFP from the stem cell-specific s-SHIP promoter to mark putative stem cells during postnatal prostate development. Here we show that cells identified by ... Read more >>

Oncotarget (Oncotarget)
[2016, 7(20):29228-29244]

Cited: 1 time

View full text PDF listing >>



Activation of P-TEFb by Androgen Receptor-Regulated Enhancer RNAs in Castration-Resistant Prostate Cancer.

Yu Zhao, Liguo Wang, Shancheng Ren, Lan Wang, Patrick R Blackburn, Melissa S McNulty, Xu Gao, Meng Qiao, Robert L Vessella, Manish Kohli, Jun Zhang, R Jeffrey Karnes, Donald J Tindall, Youngsoo Kim, Robert MacLeod, Stephen C Ekker, Tiebang Kang, Yinghao Sun, Haojie Huang,

The androgen receptor (AR) is required for castration-resistant prostate cancer (CRPC) progression, but the function and disease relevance of AR-bound enhancers remain unclear. Here, we identify a group of AR-regulated enhancer RNAs (e.g., PSA eRNA) that are upregulated in CRPC cells, patient-derived xenografts (PDXs), and patient tissues. PSA eRNA binds ... Read more >>

Cell Rep (Cell reports)
[2016, 15(3):599-610]

Cited: 26 times

View full text PDF listing >>



Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.

Martine P Roudier, Brian R Winters, Ilsa Coleman, Hung-Ming Lam, Xiaotun Zhang, Roger Coleman, Lisly Chéry, Lawrence D True, Celestia S Higano, Bruce Montgomery, Paul H Lange, Linda A Snyder, Shiv Srivastava, Eva Corey, Robert L Vessella, Peter S Nelson, Aykut Üren, Colm Morrissey,

The TMPRSS2-ERG gene fusion is detected in approximately half of primary prostate cancers (PCa) yet the prognostic significance remains unclear. We hypothesized that ERG promotes the expression of common genes in primary PCa and metastatic castration-resistant PCa (CRPC), with the objective of identifying ERG-associated pathways, which may promote the transition ... Read more >>

Prostate (The Prostate)
[2016, 76(9):810-822]

Cited: 15 times

View full text PDF listing >>



Epithelial mesenchymal-like transition occurs in a subset of cells in castration resistant prostate cancer bone metastases.

Maahum Haider, Xiaotun Zhang, Ilsa Coleman, Nolan Ericson, Lawrence D True, Hung-Ming Lam, Lisha G Brown, Melanie Ketchanji, Belinda Nghiem, Bryce Lakely, Roger Coleman, Bruce Montgomery, Paul H Lange, Martine Roudier, Celestia S Higano, Jason H Bielas, Peter S Nelson, Robert L Vessella, Colm Morrissey,

TGFβ is a known driver of epithelial-mesenchymal transition (EMT) which is associated with tumor aggressiveness and metastasis. However, EMT has not been fully explored in clinical specimens of castration-resistant prostate cancer (CRPC) metastases. To assess EMT in CRPC, gene expression analysis was performed on 149 visceral and bone metastases from ... Read more >>

Clin. Exp. Metastasis (Clinical & experimental metastasis)
[2016, 33(3):239-248]

Cited: 12 times

View full text PDF listing >>



Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer.

Akash Kumar, Ilsa Coleman, Colm Morrissey, Xiaotun Zhang, Lawrence D True, Roman Gulati, Ruth Etzioni, Hamid Bolouri, Bruce Montgomery, Thomas White, Jared M Lucas, Lisha G Brown, Ruth F Dumpit, Navonil DeSarkar, Celestia Higano, Evan Y Yu, Roger Coleman, Nikolaus Schultz, Min Fang, Paul H Lange, Jay Shendure, Robert L Vessella, Peter S Nelson,

Tumor heterogeneity may reduce the efficacy of molecularly guided systemic therapy for cancers that have metastasized. To determine whether the genomic alterations in a single metastasis provide a reasonable assessment of the major oncogenic drivers of other dispersed metastases in an individual, we analyzed multiple tumors from men with disseminated ... Read more >>

Nat. Med. (Nature medicine)
[2016, 22(4):369-378]

Cited: 206 times

View full text PDF listing >>



Addition of PSMA ADC to enzalutamide therapy significantly improves survival in in vivo model of castration resistant prostate cancer.

Vincent A DiPippo, Holly M Nguyen, Lisha G Brown, William C Olson, Robert L Vessella, Eva Corey,

Despite multiple new therapies available to patients with advanced castration-resistant prostate cancer (CRPC), the overall survival benefit still remains relatively short. Therefore, it is important to investigate additional treatment options that could achieve greater efficacy. Because of tumor heterogeneity and the development of resistance to treatment with single agents, combination ... Read more >>

Prostate (The Prostate)
[2016, 76(3):325-334]

Cited: 12 times

View full text PDF listing >>



Conversion of Prostate Adenocarcinoma to Small Cell Carcinoma-Like by Reprogramming.

Gisely T Borges, Eneida F Vêncio, Sue-Ing Quek, Adeline Chen, Diego M Salvanha, Ricardo Z N Vêncio, Holly M Nguyen, Robert L Vessella, Christopher Cavanaugh, Carol B Ware, Pamela Troisch, Alvin Y Liu,

The lineage relationship between prostate adenocarcinoma and small cell carcinoma was studied by using the LuCaP family of xenografts established from primary neoplasm to metastasis. Expression of four stem cell transcription factor (TF) genes, LIN28A, NANOG, POU5F1, SOX2, were analyzed in the LuCaP lines. These genes, when force expressed in ... Read more >>

J. Cell. Physiol. (Journal of cellular physiology)
[2016, 231(9):2040-2047]

Cited: 5 times

View full text PDF listing >>



High-Resolution Genomic Profiling of Disseminated Tumor Cells in Prostate Cancer.

Yu Wu, Jamie R Schoenborn, Colm Morrissey, Jing Xia, Sandy Larson, Lisha G Brown, Xiaoyu Qu, Paul H Lange, Peter S Nelson, Robert L Vessella, Min Fang,

Circulating tumor cells and disseminated tumor cells (DTCs) are of great interest because they provide a minimally invasive window for assessing aspects of cancer biology, including tumor heterogeneity, a means to discover biomarkers of disease behavior, and a way to identify and prioritize therapeutic targets in the emerging era of ... Read more >>

J Mol Diagn (The Journal of molecular diagnostics : JMD)
[2016, 18(1):131-143]

Cited: 3 times

View full text PDF listing >>



Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas.

Harrison Tsai, Carlos L Morais, Mohammed Alshalalfa, Hsueh-Li Tan, Zaid Haddad, Jessica Hicks, Nilesh Gupta, Jonathan I Epstein, George J Netto, William B Isaacs, Jun Luo, Rohit Mehra, Robert L Vessella, R Jeffrey Karnes, Edward M Schaeffer, Elai Davicioni, Angelo M De Marzo, Tamara L Lotan,

Small-cell neuroendocrine differentiation in prostatic carcinoma is an increasingly common resistance mechanism to potent androgen deprivation therapy (ADT), but can be difficult to identify morphologically. We investigated whether cyclin D1 and p16 expression can inform on Rb functional status and distinguish small-cell carcinoma from adenocarcinoma.We used gene expression data and ... Read more >>

Clin. Cancer Res. (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2015, 21(24):5619-5629]

Cited: 25 times

View full text PDF listing >>



The biology and clinical implications of prostate cancer dormancy and metastasis.

Colm Morrissey, Robert L Vessella, Paul H Lange, Hung-Ming Lam,

Disseminated tumor cells (DTCs) are detected early in the disease process in prostate cancer (PCa) patients and can persist after radical prostatectomy. DTCs can remain dormant in patients with no evidence of disease for a prolonged period of time only to recur 10 or more years later. Recent advances in ... Read more >>

J. Mol. Med. (Journal of molecular medicine (Berlin, Germany))
[2016, 94(3):259-265]

Cited: 12 times

View full text PDF listing >>



Epigenetically altered miR-193b targets cyclin D1 in prostate cancer.

Kirsi M Kaukoniemi, Hanna E Rauhala, Mauro Scaravilli, Leena Latonen, Matti Annala, Robert L Vessella, Matti Nykter, Teuvo L J Tammela, Tapio Visakorpi,

Micro-RNAs (miRNA) are important regulators of gene expression and often differentially expressed in cancer and other diseases. We have previously shown that miR-193b is hypermethylated in prostate cancer (PC) and suppresses cell growth. It has been suggested that miR-193b targets cyclin D1 in several malignancies. Here, our aim was to ... Read more >>

Cancer Med (Cancer medicine)
[2015, 4(9):1417-1425]

Cited: 22 times

View full text PDF listing >>



Cellular Adhesion Promotes Prostate Cancer Cells Escape from Dormancy.

Nazanin Ruppender, Sandy Larson, Bryce Lakely, Lori Kollath, Lisha Brown, Ilsa Coleman, Roger Coleman, Holly Nguyen, Peter S Nelson, Eva Corey, Linda A Snyder, Robert L Vessella, Colm Morrissey, Hung-Ming Lam,

Dissemination of prostate cancer (PCa) cells to the bone marrow is an early event in the disease process. In some patients, disseminated tumor cells (DTC) proliferate to form active metastases after a prolonged period of undetectable disease known as tumor dormancy. Identifying mechanisms of PCa dormancy and reactivation remain a ... Read more >>

PLoS ONE (PloS one)
[2015, 10(6):e0130565]

Cited: 19 times

View full text PDF listing >>



SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer.

Xiaotun Zhang, Ilsa M Coleman, Lisha G Brown, Lawrence D True, Lori Kollath, Jared M Lucas, Hung-Ming Lam, Ruth Dumpit, Eva Corey, Lisly Chéry, Bryce Lakely, Celestia S Higano, Bruce Montgomery, Martine Roudier, Paul H Lange, Peter S Nelson, Robert L Vessella, Colm Morrissey,

The neuroendocrine phenotype is associated with the development of metastatic castration-resistant prostate cancer (CRPC). Our objective was to characterize the molecular features of the neuroendocrine phenotype in CRPC.Expression of chromogranin A (CHGA), synaptophysin (SYP), androgen receptor (AR), and prostate-specific antigen (PSA) was analyzed by IHC in 155 CRPC metastases from ... Read more >>

Clin. Cancer Res. (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2015, 21(20):4698-4708]

Cited: 50 times

View full text PDF listing >>



Recurrent SKIL-activating rearrangements in ETS-negative prostate cancer.

Matti Annala, Kati Kivinummi, Joonas Tuominen, Serdar Karakurt, Kirsi Granberg, Leena Latonen, Antti Ylipää, Liisa Sjöblom, Pekka Ruusuvuori, Outi Saramäki, Kirsi M Kaukoniemi, Olli Yli-Harja, Robert L Vessella, Teuvo L J Tammela, Wei Zhang, Tapio Visakorpi, Matti Nykter,

Prostate cancer is the third most common cause of male cancer death in developed countries, and one of the most comprehensively characterized human cancers. Roughly 60% of prostate cancers harbor gene fusions that juxtapose ETS-family transcription factors with androgen regulated promoters. A second subtype, characterized by SPINK1 overexpression, accounts for ... Read more >>

Oncotarget (Oncotarget)
[2015, 6(8):6235-6250]

Cited: 12 times

View full text PDF listing >>



CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.

Nobuyuki Ishikura, Hiromitsu Kawata, Ayako Nishimoto, Ryo Nakamura, Toshiaki Tsunenari, Miho Watanabe, Kazutaka Tachibana, Takuya Shiraishi, Hitoshi Yoshino, Akie Honma, Takashi Emura, Masateru Ohta, Toshito Nakagawa, Takao Houjo, Eva Corey, Robert L Vessella, Yuko Aoki, Haruhiko Sato,

Resistance of prostate cancer to castration is currently an unavoidable problem. The major mechanisms underlying such resistance are androgen receptor (AR) overexpression, androgen-independent activation of AR, and AR mutation. To address this problem, we developed an AR pure antagonist, CH5137291, with AR nuclear translocation-inhibiting activity, and compared its activity and ... Read more >>

Int. J. Oncol. (International journal of oncology)
[2015, 46(4):1560-1572]

Cited: 1 time

View full text PDF listing >>



Reprogramming of prostate cancer cells--technical challenges.

Gisely T Borges, Eneida F Vêncio, Ricardo Z N Vêncio, Robert L Vessella, Carol B Ware, Alvin Y Liu,

Prostate cancer progression is characterized by tumor dedifferentiation. Cancer cells of less differentiated tumors have a gene expression/transcriptome more similar to that of stem cells. In dedifferentiation, cancer cells may follow a specific program of gene expression changes to a stem-like state. In order to treat cancer effectively, the stem-like ... Read more >>

Curr Urol Rep (Current urology reports)
[2015, 16(1):468]

Cited: 1 time

View full text PDF listing >>



Advertisement

Disclaimer
1.1412 s